Each year I make a list of predictions for the year to come for the stem cell and regenerative medicine field. Then about a year later I grade myself on how I did as that year winds down. Here’s how I did in 2016. For 2017, late in 2016 I made 20 stem cell predictions. Let’s […]
Grading my twenty 2017 stem cell predictions Read More »
In a nutshell, what does all of this week’s big FDA developments on stem cells and regenerative medicine mean for stem cell clinics? There’s much to be upbeat about so overall I’d say it’s good news, but I see three significant potential problems too. Dang. The good news is that the FDA seems determined to
Deconstructing FDA Mixed Bag Approach to Stem Cell Clinics Read More »
The ability of for-profit stem cell clinics to pitch unproven, risky stem cell offerings to patients may soon get much tougher in Australia. The country’s Therapeutic Goods Administration (TGA), which has some similar responsibilities there as the FDA does here in the U.S., announced planned new reforms that’ll put stem cell clinics under more scrutiny and more
Australia takes big step to curtail dangerous stem cell clinics Read More »
Time for some science humor. For past attempts at humor on this blog see here. Today, I’m asking: if science was more like sports such as football, soccer, basketball, etc., what penalties and fouls would us scientists get? Here is a humorous look at the things we mess up in small or mondo ways as
Science humor: penalties we’d get if research was like sports Read More »
Here are some stem cell weekend reads for your enjoyment along with various links and headlines. Some science pubs that caught my eye: Human Neural Stem Cell Biodistribution and Predicted Tumor Coverage by a Diffusible Therapeutic in a Mouse Glioma Model High-Content Screening in hPSC-Neural Progenitors Identifies Drug Candidates that Inhibit Zika Virus Infection in
TGIF: stem cell weekend reads & links Read More »
In December of each year I make a list of stem cell predictions for the coming year, and I made 20 such predictions for 2017 so I’m wondering how I’m doing so far on these now that it’s June. Below is my work-in-progress scorecard for these so far. Positive news from Asterias on trial for stem cell-based
2017 stem cell predictions: score card at 1/2-way point Read More »
Over at the California Stem Cell Report, David Jensen is reporting on some good news from CIRM for California on the stem cell clinical trial front. Stem cell biotechs Asterias and Capricor have stem cell trials supported by 20+ million in CIRM funding each and have been hitting milestones. These trials are progressing and so far have good safety
Upbeat prospects for some California clinical trial efforts from CIRM Read More »
Ring the bell for a stem cell milestone, specifically for iPS cell work. There’s been a whole lot of commotion about the NEJM article yesterday documenting the experiences of three women with macular degeneration who were blinded by non-FDA approved stem cell eye injections of fat stem cells at a business in Florida, but in the
Takahashi team IPS cell vision paper marks major stem cell milestone Read More »
Each year I make a list of predictions for the stem cell and regenerative medicine field for the coming new year. Later in this post I list my top 20 stem cell predictions for 2017. In looking at my past predictions I realized this will now be my 7th year doing stem cell/regenerative medicine yearly predictions.
Stem Cell Predictions for 2017 Read More »
Recently I had the opportunity to talk with the leadership of Asterias, a California biotech doing exciting clinical research using stem cells as the basis for treatment of spinal cord injury. The interview covers the past (Geron patients), present, and future. I spoke with Asterias President and CEO Stephen Cartt and CMO Edward Wirth. How
Asterias interview: stem cell spinal cord injury trials advance Read More »